Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05857995 · ClinicalTrials.gov registry record · NA

Precision Lung Cancer Survivorship Care Intervention

A NA study of Lung Cancer and Cancer, Lung, sponsored by Jerod L Stapleton, PhD.

Recruiting
Registry status
NA
Development phase
300
Enrollment target
1
Study location

NCT05857995: Recruiting NA study of Lung Cancer and Cancer, Lung, sponsored by Jerod L Stapleton, PhD.

NCT05857995 is a NA study of Lung Cancer and Cancer, Lung that is actively recruiting participants, run by Jerod L Stapleton, PhD. The registered enrollment target is 300 participants, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05857995, a NA study of Lung Cancer and Cancer, Lung, is actively recruiting participants, sponsored by Jerod L Stapleton, PhD.

RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
1
Study location

Study Summary

The overarching goal of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program is to reduce the burden of lung cancer by offering an innovative survivorship care approach that improves lung cancer quality of life, overcomes lung cancer stigma, and helps survivors engage with care. The project involves a two-group parallel randomized clinical trial comparing the impact of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program (KLCLCSC) among lung cancer survivors (N=300) against an enhanced usual care condition (bibliotherapy+assessment) on quality of life outcomes.

Primary Outcome

The Functional Assessment of Cancer Therapy-Lung (FACT-L) is a 36-item self-report instrument that measures quality life. Scores range from 0 to 144 with higher scores indicating better quality of life.

Interventions

  • BEHAVIORAL Enhanced Usual Care
  • BEHAVIORAL Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program

Study Locations (1)

Kentucky

  • Markey Cancer Center - Lexington

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2024-08-16
Est. Completion 2028-03-31
Phase NA
Jerod L Stapleton, PhD

3 total trials

What NCT05857995 shows while recruiting

NCT05857995 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 935-participant average among 409 other Lung Cancer trials with a reported enrollment target (68% lower).

The record links to 10 conditions, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Enhanced Usual Care is the first listed.

NCT05857995 reports a single indexed study location in Kentucky.

Frequently Asked Questions

What is clinical trial NCT05857995 about?

NCT05857995 is a clinical study titled "Precision Lung Cancer Survivorship Care Intervention". The overarching goal of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care program is to reduce the burden of lung cancer by offering an innovative survivorship care approach that improves lung cancer quality of life, overcomes lung cancer stigma, and helps survivors engage with care. Th...

What is the current status of trial NCT05857995?

This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2024-08-16. Estimated completion is 2028-03-31.

What conditions does trial NCT05857995 study?

This clinical trial studies the following conditions: Lung Cancer, Cancer, Lung, Pulmonary Neoplasm, Pulmonary Cancer, Neoplasms, Lung.

What interventions are being tested in trial NCT05857995?

The interventions under investigation include: Enhanced Usual Care (BEHAVIORAL), Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT05857995?

This trial is sponsored by Jerod L Stapleton, PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05857995 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05857995's enrollment target sits among peer trials

300 99th of 409 higher than 308 of 409 other Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05857995, the US trial registry maintained by the National Library of Medicine. NCT05857995 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.